CA Orange의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 25개가 Orange 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
피험자 모집 중2/3상
- Providence St. Joseph Hospital, Orange
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
피험자 모집 중3상
- University of California, Irvine Health, Orange
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
피험자 모집 중2상
- University of California Irvine, Orange
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
피험자 모집 중3상
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 4002), Orange
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중2상
- St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange
- University of California Irvine, Orange
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
피험자 모집 중3상
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
피험자 모집 중1상
- University of California - Irvine, Orange
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
피험자 모집 중2/3상
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
피험자 모집 중1/2상
- UC IRVINE Health, Orange
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
피험자 모집 중1상
- University of California Irvine Medical Center, Orange
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
피험자 모집 중3상
- Clinical Study Site, Orange
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
피험자 모집 중3상
- University of California Irvine, Orange
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
피험자 모집 중2상
- The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
피험자 모집 중3상
- University of California Irvine, Orange
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
피험자 모집 중3상
- Providence St. Joseph Hospital, Orange
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
피험자 모집 중3상
- Research Site, Orange
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
피험자 모집 중1상
- UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
피험자 모집 중1/2상
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
피험자 모집 중1상
- Research Site, Orange
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
피험자 모집 중3상
- UCI Chao Family Comprehensive Cancer Center, Orange
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
피험자 모집 중1/2상
- UC Irvine/Chao Family Comprehensive Cancer Center, Orange
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
피험자 모집 중1상
- Research Site, Orange
A Study of VET3-TGI in Patients With Solid Tumors
피험자 모집 중1상
- UC Irvine Health, Orange
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
피험자 모집 중관찰 연구
- Chao Family Comprehensive Cancer Center University of California, Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Orange
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 121개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 57개
- Washington, DC연구 55개
Orange의 다른 연구
- 전이성 암연구 20개
- 대장직장암연구 16개
- 난소암연구 16개
- 췌장암연구 15개
- 흑색종연구 14개
- 간암 (간세포암종)연구 14개
- 유방암연구 14개
- 폐암연구 14개
- 전립선암연구 14개
- 위암연구 13개
- 암 (전체)연구 13개
- 급성 골수성 백혈병연구 13개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.